SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

Absolute Bronchial Hyper-responsiveness up to 18 Months

Data for this outcome measure was not collected.

Time frame: Up to 18 months

Change in Bronchial Hyper-responsiveness From Baseline to 18 Months

Data for this outcome measure was not collected.

Time frame: Baseline (Day 0) to 18 months

Number of Symptom-free Days and Nights Without Use of Rescue Medication

The rescue medications used for exacerbations included Ventoline Diskus® 200 mcg/dose inhalations as required and oral Prednisolone 25 mg per day for five days, and when necessary, ten days. Data for this outcome measure was not collected.

Time frame: Up to 18 months

Number of Exacerbations: in Total and by Degree of Severity

Severe exacerbation: needed hospitalization/emergency unit visit. Moderate exacerbation: Needed oral cortico-steroid or adding inhaled Flixotide to maintenance study medicine; decrease in morning or evening peak expiratory flow (PEF) \> 30% during ≥ 2 following days from Baseline (Day 0). Mild exacerbation: any night symptoms ≥ 3 consecutive, or night symptoms ≥ 2 consecutive nights in case symptoms have been scored ≥ 2 during at least one night, Day symptoms scored ≥ 2 during ≥ 4 following days, or Day symptoms scored ≥ 3 during ≥ 3 following days, or Day symptoms scored ≥ 4 during ≥ 2 following days, or rescue medication use ≥ 2 occasions per day for ≥ 4 following days, or rescue medication use ≥ 3 occasions per day for ≥ 3 following days, or rescue medication use ≥ 4 occasions per day for ≥ 2 following days, or decrease in morning/evening PEF \>20% during ≥ 2 following days from Baseline (Day 0). Number of total exacerbations and severe, moderate and mild exacerbations are presented.